NO20013987L - Kombinasjoner av formoterol og flutikasonpropionat mot astma - Google Patents

Kombinasjoner av formoterol og flutikasonpropionat mot astma

Info

Publication number
NO20013987L
NO20013987L NO20013987A NO20013987A NO20013987L NO 20013987 L NO20013987 L NO 20013987L NO 20013987 A NO20013987 A NO 20013987A NO 20013987 A NO20013987 A NO 20013987A NO 20013987 L NO20013987 L NO 20013987L
Authority
NO
Norway
Prior art keywords
formoterol
asthma
combinations
fluticasone propionate
fluticasone
Prior art date
Application number
NO20013987A
Other languages
English (en)
Other versions
NO20013987D0 (no
Inventor
Ian Francis Hassan
Jeremy Guy Clarke
Henry Luke Danahay
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013987(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20013987L publication Critical patent/NO20013987L/no
Publication of NO20013987D0 publication Critical patent/NO20013987D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
NO20013987A 1999-02-18 2001-08-16 Kombinasjoner av formoterol og flutikasonpropionat mot astma NO20013987D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903759.0A GB9903759D0 (en) 1999-02-18 1999-02-18 Organic compounds
PCT/EP2000/001270 WO2000048587A1 (en) 1999-02-18 2000-02-16 Combinations of formoterol and fluticasone propionate for asthma

Publications (2)

Publication Number Publication Date
NO20013987L true NO20013987L (no) 2001-08-16
NO20013987D0 NO20013987D0 (no) 2001-08-16

Family

ID=10848051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013987A NO20013987D0 (no) 1999-02-18 2001-08-16 Kombinasjoner av formoterol og flutikasonpropionat mot astma

Country Status (32)

Country Link
US (4) US20020103260A1 (no)
EP (1) EP1152753B1 (no)
JP (1) JP2002537249A (no)
KR (2) KR20010102205A (no)
CN (1) CN1339965A (no)
AR (1) AR022609A1 (no)
AT (1) ATE266393T1 (no)
AU (1) AU758999B2 (no)
BR (1) BR0008276A (no)
CA (1) CA2368537A1 (no)
CO (1) CO5140098A1 (no)
CZ (1) CZ20012976A3 (no)
DE (1) DE60010662T2 (no)
DK (1) DK1152753T3 (no)
ES (1) ES2220411T3 (no)
GB (1) GB9903759D0 (no)
HK (1) HK1042429A1 (no)
HU (1) HUP0200852A3 (no)
ID (1) ID29437A (no)
IL (1) IL144061A (no)
MY (1) MY126768A (no)
NO (1) NO20013987D0 (no)
NZ (1) NZ513526A (no)
PE (1) PE20001545A1 (no)
PL (1) PL349856A1 (no)
PT (1) PT1152753E (no)
RU (1) RU2249454C2 (no)
SK (1) SK11842001A3 (no)
TR (1) TR200102110T2 (no)
TW (1) TWI229601B (no)
WO (1) WO2000048587A1 (no)
ZA (1) ZA200105391B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB2392915B (en) * 1999-09-11 2004-04-28 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
GB2385596B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd Container for pharmaceutical formulation of fluticasone propionate
DE60031504T2 (de) 1999-09-11 2007-04-05 Glaxo Group Ltd., Greenford Fluticasonpropionat arzneizubereitung
JP2003531123A (ja) * 2000-04-13 2003-10-21 イノバータ・バイオミッド・リミテッド 医薬品
GB0009591D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
PL365736A1 (en) * 2001-02-06 2005-01-10 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
CZ301676B6 (cs) * 2001-03-30 2010-05-19 Jagotec Ag Farmaceutický suspenzní aerosolový prípravek pro inhalaci a použití soli karboxylové kyseliny
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
WO2003066033A1 (en) † 2002-02-04 2003-08-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
US8273331B2 (en) 2002-08-21 2012-09-25 Norton Healthcare Ltd. Inhalation compositions
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN107412212B (zh) 2009-05-29 2021-01-22 珍珠治疗公司 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011093811A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical preparations comprising formoterol and fluticasone
WO2012049444A1 (en) * 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
SG194896A1 (en) * 2011-05-17 2013-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
KR20150002774A (ko) 2012-04-11 2015-01-07 시플라 리미티드 아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
RU2696582C2 (ru) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Способы и системы кондиционирования дисперсных кристаллических материалов

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
WO1998041193A1 (en) * 1997-03-20 1998-09-24 Schering Corporation Preparation of powder agglomerates

Also Published As

Publication number Publication date
HUP0200852A2 (en) 2002-08-28
US20020103260A1 (en) 2002-08-01
EP1152753A1 (en) 2001-11-14
MY126768A (en) 2006-10-31
BR0008276A (pt) 2001-11-06
ATE266393T1 (de) 2004-05-15
CZ20012976A3 (cs) 2001-11-14
KR20070104955A (ko) 2007-10-29
ZA200105391B (en) 2002-06-21
TWI229601B (en) 2005-03-21
PL349856A1 (en) 2002-09-23
PT1152753E (pt) 2004-09-30
NZ513526A (en) 2004-01-30
TR200102110T2 (tr) 2001-10-22
AR022609A1 (es) 2002-09-04
ES2220411T3 (es) 2004-12-16
WO2000048587A1 (en) 2000-08-24
DK1152753T3 (da) 2004-08-16
US20040101487A1 (en) 2004-05-27
RU2249454C2 (ru) 2005-04-10
US20100034890A1 (en) 2010-02-11
CN1339965A (zh) 2002-03-13
CO5140098A1 (es) 2002-03-22
IL144061A (en) 2005-12-18
DE60010662D1 (de) 2004-06-17
EP1152753B1 (en) 2004-05-12
ID29437A (id) 2001-08-30
US20050287079A1 (en) 2005-12-29
GB9903759D0 (en) 1999-04-14
JP2002537249A (ja) 2002-11-05
PE20001545A1 (es) 2001-01-29
AU2911500A (en) 2000-09-04
KR20010102205A (ko) 2001-11-15
NO20013987D0 (no) 2001-08-16
HK1042429A1 (en) 2002-08-16
HUP0200852A3 (en) 2004-04-28
SK11842001A3 (sk) 2001-12-03
CA2368537A1 (en) 2000-08-24
DE60010662T2 (de) 2005-05-19
AU758999B2 (en) 2003-04-03
IL144061A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
NO20013987D0 (no) Kombinasjoner av formoterol og flutikasonpropionat mot astma
NO2019003I1 (no) Kombinasjon av formoterolfumarat dihydrat og beklometason-dipropionat
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
NO20006253L (no) Anvendelse av et preparat omfattende formoterol og budesonid for forebyggelse eller behandling av en akutt astmatilstand
NO20016143D0 (no) Amfifile legemiddel-oligomer-konjugater med hydrolyserbare lipofile komponenter og fremgangsmåter for fremstilling oganvendelse av det samme
NO20041005L (no) Fremgangsmate og anordning for sammensening av gjenfestbare absorberende klesplagg
NO20014679L (no) Ledd/navsammenstilling og fremgangsmåte for fremstilling
NO20023342D0 (no) Fremgangsmåte for fjernelse av NOX og N2O
NO20014680D0 (no) Festeanordning for ledd/navsammenstilling og fremgangsmåte for anvendelse
AU4672301A (en) Medical combinations comprising formoterol and fluticasone proprionate
AU4671601A (en) Medical combinations comprising formoterol and budesonide
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20014648L (no) Forbindelser og metoder for behandling av astma, allergi og inflammatoriske sykdommer
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20021784L (no) Anvendelse av dipyridamol eller mopidamol for fremstilling av et medikament for behandling og forebygging av fibrin-avhengigmikrosirkulasjonsforstyrrelser
NO20030899L (no) Anvendelse av salmeterol og fluticasonpropionat kombinasjon
AU2002237400A1 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
DK0889051T3 (da) Triterpenderivater og midler mod leversygdomme
SI1152753T1 (en) Combinations of formoterol and fluticasone propionate for asthma
AU2001284287A1 (en) Pharmaceutical combination containing salmeterol and fluticasone
NO942611D0 (no) Anvendelse av nikotin og innretning for inhalering av nikotin
NO995314D0 (no) For og anvendelse av slikt for

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application